4-(1-哌嗪基)苯甲酸乙酯 | 80518-57-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(1-哌嗪基)苯甲酸乙酯
• 中文别名: (4-哌嗪-1-基)苯甲酸乙酯
• 英文名称: ethyl 4-(piperazin-1-yl)benzoate
• 英文别名: 4-piperazin-1-yl-benzoic acid ethyl ester；ethyl 4-piperazin-1-ylbenzoate
• CAS: 80518-57-6
• 化学式: C₁₃H₁₈N₂O₂
• 分子量: 234.298
• InChiKey: OQEHTFFLOHTFSB-UHFFFAOYSA-N

物化性质

• 熔点：
  102-105°C
• 沸点：
  388.9±27.0 °C(Predicted)
• 密度：
  1.104±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、DMSO、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 干燥 |

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Ethyl 4-(1-Piperazinyl)Benzoate
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 234,29 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
Ethyl 4-(1-Piperazinyl)Benzoate
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
Ethyl 4-(1-Piperazinyl)Benzoate
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

应用(4-哌嗪-1-基)苯甲酸乙酯是苯基哌嗪类抗抑郁症药物的中间体，尤其是合成如阿立哌唑等调节神经类药物的关键原料。

制备将52.3克（0.44摩尔）氯化亚砜溶解于10毫升氯仿中，置于装有回流冷凝管和冰水浴的四口烧瓶中。机械搅拌下用水吸收尾气。缓慢滴加二乙醇胺21.5克（0.2摩尔）与15毫升氯仿的混合液，控制反应液温度不超过30℃，整个过程持续约3小时。滴加完毕后撤去冰水浴，在室温下继续反应1小时。然后逐渐升温至50℃，保持此温度反应0.5小时，停止加热并冷却至室温。抽滤得到白色微黄绿色固体，用无水乙醇重结晶，最终获得白色针状晶体。

将β, β′-二氯代二乙基胺盐酸盐（12.7克，0.07摩尔）溶解于55毫升水中，置于装有回流冷凝管的四口烧瓶中。机械搅拌下加热使固体完全溶解，滴加相应量的取代苯胺，并每半小时检测pH一次，使用50%碳酸钠水溶液调节反应体系pH至6且不再变化为止。停止加热，静置冷却至室温后过滤，滤饼用水和无水乙醇各洗涤两次并烘干，最终获得白色晶体。

反应信息

• 作为反应物：
  描述：

  4-(1-哌嗪基)苯甲酸乙酯 在 bis-triphenylphosphine-palladium(II) chloride 、 水 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 溶剂黄146 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 9.0h， 生成 4-[4-(4'-氯联苯-2-基甲基)哌嗪-1-基]苯甲酸
  参考文献：
  名称：

  [EN] INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS
  [FR] INHIBITION DU LYMPHOME 2 À CELLULES B (BCL -2) ET DES PROTÉINES APPARENTÉES

  摘要：

  新型化合物抑制抗凋亡蛋白B细胞淋巴瘤2（Bcl-2）和Bcl-XL，包括本文披露的式（I）和式（II）的化合物，以及含有Bcl-2抑制剂化合物的脂质体组合物。这些组合物对于癌症的治疗是有用的。

  公开号：

  WO2017123616A1
• 作为产物：
  描述：

  4-(4-(乙氧基羰基)苯基)哌嗪-1-羧酸叔丁酯 在 三氟乙酸 作用下， 生成 4-(1-哌嗪基)苯甲酸乙酯
  参考文献：
  名称：

  用于合成芳族胺的电化学交叉脱氢芳构化方案

  摘要：

  在没有金属催化剂和化学氧化剂的情况下将胺引入芳烃中是一项综合挑战。在这里，我们报告了饱和环己酮和胺的电化学交叉脱氢芳构化 (ECDA) 反应在没有额外金属催化剂和化学氧化剂的情况下构建苯胺的第一个例子。该反应展示了包括杂环酮在内的广泛的环己酮，提供了多种具有不同功能的芳香胺，在生物活性化合物的合成中显示出巨大的潜力。

  DOI：

  10.1021/acs.orglett.1c04129
• 作为试剂：
  描述：

  4-(1-哌嗪基)苯甲酸乙酯 、 3-(3,5-二叔丁基-4-羟基苯基)丙酸 在 4-(1-哌嗪基)苯甲酸乙酯 、 乙醚 、 盐酸 、 水 、 碳酸氢钠 、 Sodium sulfate-III 、 乙醇 作用下， 以 邻二甲苯 为溶剂， 反应 28.0h， 以to give 32.0 g的产率得到Ethyl 4-{1-[3-(3,5-di-tert.-butyl-4-hydroxyphenyl)-propionyl]-piperazin-4-yl}-benzoate
  参考文献：
  名称：

  Piperazine-substituted aryl and aralkyl carboxylic acids useful for

  摘要：

  本发明涉及新的羧酸衍生物，其制备过程以及包含它们的用于脂质降低和血小板聚集的药物组合物，以及治疗由过量脂质或血小板聚集引起的疾病的方法。根据本发明，新的羧酸衍生物是具有以下通式的化合物： ##STR1## 其中A是一个价键或低级烷基链，B是一个价键或饱和或不饱和的低级烷基链，R是氢，可以被羟基，羧基，磺酸或可选的取代的苯氧基取代的烷基基团，或R是一个芳基烷基基团，其中芳基部分可以被取代，烷基部分可选不饱和，可以含有高达4个碳原子，或R是一个苯乙酰基基团，其中苯基部分可选取代，或R是从脂肪族，芳基脂肪族或芳香族羧酸或磺酸派生的酰基基团，或R是一个芳基基团，可选取代，但当A是一个价键时，R不能是氢，甲基，乙基，羟乙基，苯甲基或苯基，并且它们的生理上可接受的盐，酯和酰胺。

  公开号：

  US04616086A1

文献信息

• [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS<br/>[FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES
  申请人：CHEMOCENTRYX INC

  公开号：WO2003105853A1

  公开（公告）日：2003-12-24

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。
• [EN] HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS<br/>[FR] DERIVES HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA STEAROYL-COA DESATURASE
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2006034441A1

  公开（公告）日：2006-03-30

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明公开了治疗哺乳动物，尤其是人类患有SCD介导的疾病或症状的方法，其中所述方法包括向需要的哺乳动物施用式(I)的化合物，其中在此处定义了x、y、J、K、W、V、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a。还公开了包含式(I)化合物的药物组合物。
• NOVEL COMPOUNDS
  申请人：GRAUERT Matthias

  公开号：US20130184248A1

  公开（公告）日：2013-07-18

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 have meanings given in the description.

  这项发明涉及到式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神疾病，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
• Chelating Bis(1,2,3‐triazol‐5‐ylidene) Rhodium Complexes: Versatile Catalysts for Hydrosilylation Reactions
  作者：Thanh V. Q. Nguyen、Woo‐Jin Yoo、Shū Kobayashi

  DOI：10.1002/adsc.201500875

  日期：2016.2.4

  reactions. However, the substrates were mostly limited to reactive carbonyl compounds (aldehydes and ketones) or carbon‐carbon multiple bonds. Here, we describe the application of newly‐developed chelating bis(tzNHC)‐rhodium complexes (tz=1,2,3‐triazol‐5‐ylidene) for several reductive transformations. With these catalysts, the formal reductive methylation of amines using carbon dioxide, the hydrosilylation

  NHC-铑配合物（NHC = N-杂环卡宾）已被广泛用作氢化硅烷化反应的有效催化剂。但是，底物主要限于反应性羰基化合物（醛和酮）或碳-碳多重键。在这里，我们描述了新开发的螯合双（tz NHC）-铑配合物（tz = 1,2,3-三唑-5-亚烷基）在几种还原转化中的应用。使用这些催化剂，已经在温和的反应条件下实现了使用二氧化碳的胺的正式还原甲基化，酰胺和羧酸的氢化硅烷化以及使用羧酸的胺的还原烷基化。
• [EN] ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS<br/>[FR] DÉRIVÉS ACYLSULFONAMIDE POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À LA SÉNESCENCE
  申请人：UNITY BIOTECHNOLOGY INC

  公开号：WO2017101851A1

  公开（公告）日：2017-06-22

  Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.

  本文件中描述了由公式(I)和(II)表示的化合物及其盐。公式(I)和(II)的化合物或盐可以用于治疗与衰老相关的疾病和失调。